Anti-cancer combination therapy

The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.

Saved in:
Bibliographic Details
Main Authors Reschke, Markus, Hilberg, Frank, Hofmann, Marco Hans, Solca, Flavio
Format Patent
LanguageEnglish
Published 14.12.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
Bibliography:Application Number: US201815995375